Background
There is little information regarding the efficacy of benralizumab in patients (pts) with asthma based on their smoking status.
Aims and Objectives
To characterize the efficacy of benralizumab in the ORBE II study according to pts smoking status.
Methods
ORBE II (NTC04648839) is a retrospective multicenter study conducted in severe eosinophilic asthma pts treated with benralizumab in Spain. For this analysis, pts were identified as never smokers and smokers (current/former).
Results
Never smokers (n=128) and smokers (n=75(6 current and 69 former)) had very similar baseline characteristics. After 1-year treatment with benralizumab, there was an 84.6% reduction in severe exacerbations among never smokers versus 92% in smokers. Improvements in symptoms and lung function were observed in both groups and were generally more pronounced in never smokers.
Conclusions
These results support the effectiveness of benralizumab in patients with severe eosinophilic asthma, regardless of their smoking status.
| Never smokers n=128 (63.1%) | Smokers n=75 (36.9%) | |||
| Baseline | Follow-up (12 months) | Baseline | Follow-up (12 months) | |
| Severe exacerbations, mean (SD) | 2.6 (2.5) | 0.4 (0.9) | 2.5 (1.9) | 0.2 (0.7) |
| Pre-BD FEV1 value (L), mean (SD) | 2.0 (0.8) | 2.2 (0.8) | 1.8 (0.8) | 2.2 (0.7) |
| Pts with % FEV1 preBD ?80%, n (%) | 32 (30.2) | 46 (51.7) | 18 (28.6) | 16 (35.6) |
| % pts with % FEV1/FVC preBD ?70% | 29 (30.5) | 35 (41.7) | 17 (32.1) | 16 (41.0) |
| Pts with FEV1 pre-BD increase ?100 mL, n (%) | 55 (70.5) | 21 (58.3) | ||
| Pts with FEV1 pre-BD increase ?200 mL, n (%) | 52 (66.7) | 16 (44.4) | ||
| Pts with ACT ?20, N (%) | 15 (16.1) | 66 (82.5) | 9 (16.7) | 30 (60.0) |